Cargando…
Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0
Indoleamine 2,3-dioxygenase (IDO1) is a key regulator of immune suppression by catalyzing the oxidation of L-tryptophan. IDO1 expression has been related to poor prognosis in several cancers and to resistance to checkpoint immunotherapies. We describe the characterization of a novel small molecule I...
Autores principales: | Grobben, Yvonne, de Man, Jos, van Doornmalen, Antoon M., Muller, Michelle, Willemsen-Seegers, Nicole, Vu-Pham, Diep, Mulder, Winfried R., Prinsen, Martine B. W., de Wit, Joeri, Sterrenburg, Jan Gerard, van Cauter, Freek, den Ouden, Judith E., van Altena, Anne M., Massuger, Leon F., Uitdehaag, Joost C. M., Buijsman, Rogier C., Zaman, Guido J. R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876453/ https://www.ncbi.nlm.nih.gov/pubmed/33584686 http://dx.doi.org/10.3389/fimmu.2020.609490 |
Ejemplares similares
-
Pharmacological validation of TDO as a target for Parkinson’s disease
por: Perez‐Pardo, Paula, et al.
Publicado: (2021) -
Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites
por: den Ouden, Judith E., et al.
Publicado: (2020) -
Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158
por: Grobben, Yvonne, et al.
Publicado: (2019) -
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020
por: Kooijman, Jeffrey J., et al.
Publicado: (2022) -
Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use
por: Uitdehaag, Joost C. M., et al.
Publicado: (2014)